Genicular blocks (bupivakain)
PreclinicalSmall molecule
Genicular blocks (bupivakain) is one of 89 small molecule programs targeting Total Knee Arthroplasty. It is currently in Preclinical.
3
Indications
2
Total Trials
1
Active Trials
88
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
143 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Toradol
RochePreclinical
Bayer Aspirin
BayerPreclinical
Cataflam
NovartisPreclinical
Enbrel
IImmunex
Preclinical
Glucophage
EMD SeronoPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Catapres
Boehringer IngelheimPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Osteoarthritis1 trial
Effects of Ultrasound-guided Genicular Nerve Block in Knee Osteoarthritis Patients on Proprioception and Static Balance
Completed·—·N/A·NCT06527651·22 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMersin University